mRNA 1010
Alternative Names: mRNA-1010; Quadrivalent seasonal influenza mRNA vaccine - Moderna; Seasonal influenza vaccine - Moderna TherapeuticsLatest Information Update: 09 Jul 2025
At a glance
- Originator Moderna Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 30 Jun 2025 Adverse events and efficacy data from phase III trial in Influenza virus infections released by Moderna
- 11 Mar 2025 Moderna Therapeutics re-initiates enrolment in a phase II trial for Influenza virus infections (Prevention) in USA (IM) (NCT05606965)
- 19 Sep 2024 Moderna Therapeutics plans a phase III trial for Influenza virus infection (Prevention) in Belgium, Bulgaria, Canada, Estonia, Finland, Georgia, Germany, South Korea, Taiwan, United Kingdom and USA (IM, Injection) (NCT06602024)